中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

26 records (took 0.035 seconds)

    NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER
    5.
    发明申请
    NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER 审中-公开
    新型抗CD38抗体用于治疗癌症

    公开(公告)号：WO2008047242A2

    公开(公告)日：2008-04-24

    申请号：PCT/IB2007004172

    申请日：2007-10-16

    Applicant: SANOFI AVENTIS ,  PARK PETER U ,  BARTLE LAURA M ,  SKALETSKAYA ANNA ,  GOLMAKHER VIKTOR S ,  TAVARES DANIEL ,  DECKERT JUTTA ,  MIKOL VINCENT ,  BLANC VERONIQUE

    Inventor： PARK PETER U ,  BARTLE LAURA M ,  SKALETSKAYA ANNA ,  GOLMAKHER VIKTOR S ,  TAVARES DANIEL ,  DECKERT JUTTA ,  MIKOL VINCENT ,  BLANC VERONIQUE

    IPC: C07K16/00

    CPC classification number: G01N33/57426 ,  A61K47/6803 ,  A61K47/6867 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/462 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  G01N33/57484 ,  G01N2333/924

    Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38 + cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.

    Abstract translation: 抗体，人源化抗体，表面重构表面抗体，抗体片段，衍生化抗体，以及与细胞毒性剂结合的特异性结合CD38的缀合物能够通过细胞凋亡杀死CD38 + / +细胞， 介导的细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）。 所述抗体及其片段可用于治疗表达CD38蛋白的肿瘤，例如多发性骨髓瘤，慢性淋巴细胞性白血病，慢性粒细胞性白血病，急性髓性白血病或急性淋巴细胞性白血病，或治疗自身免疫疾病和炎性疾病，例如 系统性红斑狼疮，类风湿性关节炎，多发性硬化症，红斑狼疮和哮喘。 所述衍生抗体可用于表达升高水平的CD38的肿瘤的诊断和成像。 还提供了包含细胞结合剂和细胞毒性剂的细胞毒性缀合物，包含所述缀合物的治疗性组合物，使用所述缀合物抑制细胞生长和治疗疾病的方法，以及包含所述细胞毒性缀合物的试剂盒。 特别地，细胞结合剂是识别并结合CD38蛋白的单克隆抗体及其表位结合片段。

    PACKAGING STRUCTURE OF MEMS MICROPHONE
    6.
    发明申请
    PACKAGING STRUCTURE OF MEMS MICROPHONE 审中-公开
    MEMS麦克风的包装结构

    公开(公告)号：WO2007123293A1

    公开(公告)日：2007-11-01

    申请号：PCT/KR2006/003111

    申请日：2006-08-08

    Applicant: BSE Co., Ltd. ,  CHOO, Yunjai ,  PARK, Peter

    Inventor： CHOO, Yunjai ,  PARK, Peter

    IPC: H04R19/04

    CPC classification number: H04R19/005 ,  H04R19/04 ,  H05K1/189

    Abstract: The present invention relates to a packaging structure of a MEMS microphone comprising: a first case having an open first end and a second end having a sound hole formed therethrough; a flexible printed circuit board including a first region having a hole corresponding to the sound hole, the first region being attached to an inner surface of the first case, a second region having a first electrode for transmitting an electrical signal to an external device, and a connecting portion for connecting the first region and the second region; a transducer and an amplifier disposed in the first region so as to face the sound hole; and a second case sealing the open first end of the first case, the second case including an extension hole for extending the connecting portion and the second region to an outside of the second case.

    Abstract translation: 本发明涉及一种MEMS麦克风的包装结构，包括：第一壳体，其具有开放的第一端部，第二端部具有穿过其形成的声孔; 柔性印刷电路板，包括具有与声孔对应的孔的第一区域，第一区域附接到第一壳体的内表面，第二区域，具有用于将电信号传输到外部设备的第一电极，以及 用于连接第一区域和第二区域的连接部分; 设置在所述第一区域中以便面对所述声孔的换能器和放大器; 以及密封第一壳体的敞开的第一端的第二壳体，第二壳体包括用于将连接部分和第二区域延伸到第二壳体的外部的延伸孔。

    CD20 ANTIBODIES AND USES THEREOF
    8.
    发明申请
    CD20 ANTIBODIES AND USES THEREOF 审中-公开
    CD20抗体及其用途

    公开(公告)号：WO2011100403A1

    公开(公告)日：2011-08-18

    申请号：PCT/US2011/024312

    申请日：2011-02-10

    Applicant: IMMUNOGEN, INC ,  DECKERT, Jutta ,  RUI, Lingyun ,  PARK, Peter U.

    Inventor： DECKERT, Jutta ,  RUI, Lingyun ,  PARK, Peter U.

    IPC: A61K39/395 ,  C12P21/08

    CPC classification number: C07K16/2887 ,  A61K39/39541 ,  A61K47/6817 ,  A61K47/6819 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/55 ,  C12N2501/48 ,  G01N33/57426

    Abstract: CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells and has been found on B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. Conversely, it is not found on hematopoietic stem cells, pro-B cells, differentiated plasma cells or non-lymphoid tissues. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin™s lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). CD20 expressing cells are known to play a role in other diseases and disorders, including inflammation. The present invention includes anti-CD20 antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.

    Abstract translation: CD20是在B细胞表面表达的四跨连锁蛋白家族的跨膜蛋白，并且已经从外周血和淋巴组织的B细胞中发现。 CD20表达从早期B细胞前期持续到血浆细胞分化阶段。 相反，在造血干细胞，前B细胞，分化浆细胞或非淋巴组织中未发现。 除了在正常B细胞​​中表达外，CD20在B细胞衍生的恶性肿瘤如非霍奇金淋巴瘤（NHL）和B细胞慢性淋巴细胞白血病（CLL）中表达。 已知CD20表达细胞在其他疾病和病症中发挥作用，包括炎症。 本发明包括具有优异的物理和功能特性的抗CD20抗体，形式和片段; 免疫缀合物，组合物，诊断试剂，抑制生长的方法，治疗方法，改进的抗体和细胞系; 和编码相同的多核苷酸，载体和遗传构建体。

    CD20 ANTIBODIES AND USES THEREOF
    9.
    发明申请
    CD20 ANTIBODIES AND USES THEREOF 审中-公开
    CD20抗体及其用途

    公开(公告)号：WO2011100398A1

    公开(公告)日：2011-08-18

    申请号：PCT/US2011/024301

    申请日：2011-02-10

    Applicant: IMMUNOGEN, INC. ,  DECKERT, Jutta ,  TAVARES, Daniel, J. ,  PARK, Peter, U.

    Inventor： DECKERT, Jutta ,  TAVARES, Daniel, J. ,  PARK, Peter, U.

    IPC: A61K39/395 ,  C12P21/08

    CPC classification number: C07K16/2887 ,  A61K39/39541 ,  A61K47/6817 ,  A61K47/6819 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/55 ,  G01N33/57426

    Abstract: CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells and has been found on B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. Conversely, it is not found on hematopoietic stem cells, pro-B cells, differentiated plasma cells or non-lymphoid tissues. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin™s lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). CD20 expressing cells are known to play a role in other diseases and disorders, including inflammation. The present invention includes anti-CD20 antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.

    Abstract translation: CD20是在B细胞表面表达的四肽家族的跨膜蛋白，并且已经在来自外周血和淋巴组织的B细胞中发现。 CD20表达从早期前B细胞阶段持续到血浆细胞分化阶段。 相反，它在造血干细胞，前B细胞，分化浆细胞或非淋巴组织中未见。 除了在正常B细胞​​中表达之外，CD20在B细胞衍生的恶性肿瘤如非霍奇金淋巴瘤（NHL）和B细胞慢性淋巴细胞性白血病（CLL）中表达。 已知CD20表达细胞在包括炎症在内的其他疾病和病症中发挥作用。 本发明包括具有优越的物理和功能特性的抗CD20抗体，形式和片段; 免疫缀合物，组合物，诊断试剂，抑制生长的方法，治疗方法，改进的抗体和细胞系; 和编码它们的多核苷酸，载体和基因构建体。

    REINFORCED CATHETER WITH A FORMABLE DISTAL TIP
    10.
    发明申请
    REINFORCED CATHETER WITH A FORMABLE DISTAL TIP 审中-公开
    加强导管带有一个无法提供的直线

    公开(公告)号：WO1998024502A1

    公开(公告)日：1998-06-11

    申请号：PCT/US1997022539

    申请日：1997-12-08

    Applicant: TARGET THERAPEUTICS, INC. ,  PARK, Peter, Kyone ,  NITA, Henry

    Inventor： TARGET THERAPEUTICS, INC.

    IPC: A61M25/00

    CPC classification number: A61M25/0041 ,  A61L29/14 ,  A61M25/0052 ,  A61M2205/0266

    Abstract: This is a section of a catheter which self-forms a selected shape upon application of a modest amount of heat and retains that shape upon cooling and, indeed, upon any reheating. The catheter section includes in its wall a forming member which typically comprises a super-elastic alloy woven braid or at least one coil. The forming member may include other materials and components in addition to the super-elastic element of the forming member. The forming member is typically covered by at least an outer polymeric covering which holds the forming member in a first shape prior to the heating step. Upon softening of the outer layer during that heating step, the forming member self-forms into the desired second shape. The catheter section may be used either in its first shape or its second shape or in any transitional shape between the two. Often the inner lumen of the forming member may contain a second polymeric tubing member. The inner polymeric tubing member is often lubricious. The catheter sections made according to this invention may be used alone or in conjunction with other catheter sections. The more proximal sections of a catheter assembly using this concept are often substantially stiffer.

    Abstract translation: 这是导管的一部分，其在施加适量的热量时自我形成选定的形状，并且在冷却时，实际上在任何再加热时保持该形状。 导管部分在其壁上包括一个成形构件，该成形构件通常包括超弹性合金编织编织物或至少一个线圈。 除了成形构件的超弹性元件之外，成形构件可以包括其它材料和部件。 成形构件通常被至少一个外部聚合物覆盖物覆盖，其在加热步骤之前将成形构件保持在第一形状。 在该加热步骤期间软化外层时，成形构件自身形成所需的第二形状。 导管部分可以以其第一形状或其第二形状或两者之间的任何过渡形状使用。 通常，成形构件的内腔可以包含第二聚合物管构件。 内聚合物管件通常是润滑的。 根据本发明制造的导管部分可以单独使用或与其它导管部分结合使用。 使用该概念的导管组件的近侧部分通常基本上更硬。

Patent Agency Ranking